Previous 10 | Next 10 |
Summary Adaptimmune Therapeutics plans to file a BLA this year. Despite that, the stock remains depressed. Their cash position is difficult as well. For further details see: Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this event. For further details see: Adaptimmune Therapeutics (ADAP) Presents At ESMO Congress 2022 - Slideshow
U.K.-based biotech Adaptimmune Therapeutics plc ( NASDAQ: ADAP ) announced new data Friday from its Phase 1 SURPASS trial for anti-cancer agent ADP-A2M4CD8 in patients with solid tumors. The data will be part of a presentation at the European Society for Medical Oncology (ES...
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers - - Further clinical development planned in ovarian (SURPASS-3), urothelial, and head & neck cancers - - Across all t...
- Event to be held on Friday, September 9 th , at 8 a.m. EDT - Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will provide an update on its Phase 1 SURPASS trial...
Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...
Adaptimmune Therapeutics plc (ADAP) Q2 2022 Earnings Conference Call Aug 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development G...
Adaptimmune press release ( NASDAQ: ADAP ): Q2 Non-GAAP EPS of -$0.05 beats by $0.24 . Revenue of $5.54M (+78.7% Y/Y) misses by $3.16M . For further details see: Adaptimmune Non-GAAP EPS of -$0.05 beats by $0.24, revenue of $5.54M misses by $3.16M
- Reaffirming financial guidance; Company funded into early 2024 - - ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress - - Quarterly call to be held toda...
Several biotechs involved in gene editing are higher on Wednesday in the aftermath of Roche's ( OTCQX:RHHBY ) blockbuster deal with CAR-T-focused Poseida Therapeutics ( PSTX ) announced earlier today. One of the biggest gainers -- up more than 30% -- is Alaunos The...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...